Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
Olaf NickelAlexandra RockstrohJohannes WolfSusann LandgrafSven KalbitzNils KellnerMichael BorteCorinna PietschJasmin FerteyChristoph LübbertSebastian UlbertStephan BortePublished in: PloS one (2022)
Our data demonstrate that BNT162b2 vaccinated individuals generate relevant nAbs titers, which begin to decrease within three months after immunization and show lower neutralizing potential against VOCs as compared to the wildtype strain. Large proportion of vaccine-induced S1-IgG might be non-neutralizing whereas RBD-IgGAM appears to be a good surrogate marker to estimate nAb levels. A third vaccination increases the nAb response. Furthermore, the systemic vaccine does not seem to elicit readily detectable mucosal immunity.
Keyphrases
- sars cov
- immune response
- coronavirus disease
- respiratory syndrome coronavirus
- advanced non small cell lung cancer
- dengue virus
- ulcerative colitis
- electronic health record
- high glucose
- diabetic rats
- big data
- zika virus
- dendritic cells
- risk assessment
- oxidative stress
- inflammatory response
- toll like receptor
- binding protein
- epidermal growth factor receptor